Studies of the role of dysferlin's C2 domains and its effects on Ca2+ homeostasis and signaling may reveal an array of therapeutic options for individuals with LGMD2B and MM that will likely include both drug and genetic approaches. Here, DYSF is linked to Miyoshi myopathy.